Publications by authors named "Peter Ulrichts"

Claim this Profile
E
Effects of efgartigimod treatment on humoral and cellular immune responses: analysis of T-cell-dependent antibody response in cynomolgus monkeys.
Ornella Binazon, Mario Cocco, Daniel Thwaites, Christopher Cooper, Mahan Moshir, Peter Ulrichts

J Immunotoxicol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of FcRn antagonism on vaccine-induced protective immune responses against viral challenge in COVID-19 and influenza mouse vaccination models.
Prajakta Warang, Gagandeep Singh, Mahan Moshir, Ornella Binazon, Gabriel Laghlali, Peter Ulrichts

Hum Vaccin Immunother· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety profile of efgartigimod from global clinical trials across multiple immunoglobulin G-mediated autoimmune diseases.
Kelly G Gwathmey, Catherine M Broome, Matthias Goebeler, Hiroyuki Murai, Zsuzsanna Bata-Csörgo, Peter Ulrichts

Expert Rev Clin Immunol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient-specific therapeutic benefit of MuSK agonist antibody ARGX-119 in MuSK myasthenia gravis passive transfer models.
Jamie L Lim, Stine Marie Jensen, Jaap J Plomp, Bernhardt Vankerckhoven, Christa Kneip, Peter Ulrichts

iScience· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, tolerability, and efficacy of subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ADHERE): a multicentre, randomised-withdrawal, double-blind, placebo-controlled, phase 2 trial.
Jeffrey A Allen, Jie Lin, Ivana Basta, Tina Dysgaard, Christian Eggers, Peter Ulrichts

Lancet Neurol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ARGX-119 is an agonist antibody for human MuSK that reverses disease relapse in a mouse model of congenital myasthenic syndrome.
Roeland Vanhauwaert, Julien Oury, Bernhardt Vankerckhoven, Christophe Steyaert, Stine Marie Jensen, Peter Ulrichts

Sci Transl Med· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Differential effects of FcRn antagonists on the subcellular trafficking of FcRn and albumin.
Guanglong Ma, Andrew R Crowley, Liesbeth Heyndrickx, Ilse Rogiers, Eef Parthoens, Peter Ulrichts

JCI Insight· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of efgartigimod on muscle group subdomains in participants with generalized myasthenia gravis: post hoc analyses of the phase 3 pivotal ADAPT study.
Vera Bril, James F Howard, Chafic Karam, Jan L De Bleecker, Hiroyuki Murai, Peter Ulrichts

Eur J Neurol· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Fab region of IgG impairs the internalization pathway of FcRn upon Fc engagement.
Maximilian Brinkhaus, Erwin Pannecoucke, Elvera J van der Kooi, Arthur E H Bentlage, Ninotska I L Derksen, Peter Ulrichts

Nat Commun· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel treatment strategies for acetylcholine receptor antibody-positive myasthenia gravis and related disorders.
Marina Mané-Damas, Peter C Molenaar, Peter Ulrichts, Florit Marcuse, Marc H De Baets

Autoimmun Rev· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
IgG regulation through FcRn blocking: A novel mechanism for the treatment of myasthenia gravis.
Gil I Wolfe, E Sally Ward, Hans de Haard, Peter Ulrichts, Tahseen Mozaffar

J Neurol Sci· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial.
James F Howard, Vera Bril, Tuan Vu, Chafic Karam, Stojan Peric, Peter Ulrichts

Lancet Neurol· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 2 study of efgartigimod, a novel FcRn antagonist, in adult patients with primary immune thrombocytopenia.
Adrian C Newland, Blanca Sánchez-González, László Rejtő, Miklos Egyed, Nataliya Romanyuk, Peter Ulrichts

Am J Hematol· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efgartigimod improves muscle weakness in a mouse model for muscle-specific kinase myasthenia gravis.
Maartje G Huijbers, Jaap J Plomp, Inge E van Es, Yvonne E Fillié-Grijpma, Samar Kamar-Al Majidi, Peter Ulrichts

Exp Neurol· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis.
James F Howard, Vera Bril, Ted M Burns, Renato Mantegazza, Malgorzata Bilinska, Peter Ulrichts

Neurology· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans.
Peter Ulrichts, Antonio Guglietta, Torsten Dreier, Tonke van Bragt, Valérie Hanssens

J Clin Invest· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ARGX-110, a highly potent antibody targeting CD70, eliminates tumors via both enhanced ADCC and immune checkpoint blockade.
Karen Silence, Torsten Dreier, Mahan Moshir, Peter Ulrichts, Sofie M E Gabriels

MAbs· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of interaction sites for dimerization and adapter recruitment in Toll/interleukin-1 receptor (TIR) domain of Toll-like receptor 4.
Celia Bovijn, Peter Ulrichts, Anne-Sophie De Smet, Dominiek Catteeuw, Rudi Beyaert

J Biol Chem· February 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Caspase-1 targets the TLR adaptor Mal at a crucial TIR-domain interaction site.
Peter Ulrichts, Celia Bovijn, Sam Lievens, Rudi Beyaert, Jan Tavernier

J Cell Sci· January 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MAPPIT (mammalian protein-protein interaction trap) analysis of early steps in toll-like receptor signalling.
Peter Ulrichts, Irma Lemmens, Delphine Lavens, Rudi Beyaert, Jan Tavernier

Methods Mol Biol· May 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MAPPIT analysis of early Toll-like receptor signalling events.
Peter Ulrichts, Jan Tavernier

Immunol Lett· March 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MAPPIT analysis of TLR adaptor complexes.
Peter Ulrichts, Frank Peelman, Rudi Beyaert, Jan Tavernier

FEBS Lett· February 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The C-terminus of CIS defines its interaction pattern.
Delphine Lavens, Peter Ulrichts, Dominiek Catteeuw, Kris Gevaert, Joël Vandekerckhove

Biochem J· January 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunostimulatory potential of hepatitis B nucleocapsid preparations: lipopolysaccharide contamination should not be overlooked.
Peter Vanlandschoot, Freya Van Houtte, Peter Ulrichts, Jan Tavernier, Geert Leroux-Roels

J Gen Virol· February 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mapping of the leptin binding sites and design of a leptin antagonist.
Frank Peelman, Katrien Van Beneden, Lennart Zabeau, Hannes Iserentant, Peter Ulrichts

J Biol Chem· September 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis